Recent Approaches for Scientific Research in Diabetic Nephropathy

Dear Colleagues,

In the context of the global census, diabetes mellitus and its consequences, including nephropathy, affect approximately 40% of diabetic patients, which is more common in the scientific domain. Diabetic nephropathy has also been recognized as diabetic kidney disease, the term used to describe impairment of kidney function in people with both type 1 and type 2 diabetes. The major concern of kidney failure and the primary cause of diabetic death is diabetic renal disease. However, there is still no clarified explanation for how hyperglycemia and kidney injury are critically related, in recent studies. In this proposed Special Issue, the heterogeneity of diabetic nephropathy's etiology and its underlying cellular and molecular mechanisms would be deciphered. To this goal, the role of oxidative stress, inflammation, autophagy, mitochondrial dysfunction, and importantly genetic and epigenetic nephropathy risk factors would also be considered. The reversal and prevention of diabetic nephropathy have potential relevance to the oxidative-stress pathway for this particular interest, early biomarkers would also be put on particular attention as they hold considerable promise for improving knowledge and early detection of nephrotic illness.

For this Special Issue, we welcome articles, including both original research and reviews, that can enhance the better understanding and knowledge of the molecular origins of disease. The proposed submissions are focusing on, but are not restricted to:

• The comprehensive understanding of single-cell transcriptomics through single-cell RNA-seq and single-nucleus RNA-seq in studying the pathogenesis and treatment of diabetic kidney disease.
• Natural compounds/nutraceuticals and plant extracts used for both prevention and treatment of diabetic kidney disease that target certain molecular mechanistic processes.
• The relationship between diabetes-mediated kidney damage and oxidative stress, reactive oxygen species, inflammation, autophagy, and mitochondrial dysfunction.
• The application of genetic, cellular, and histopathological studies to nephropathy prediction.
• The use of nanomedicines and nanoparticles (NPs) as efficient therapeutic, diagnostic, and imaging tools for managing and treating diabetic kidney disease.

Dr. Mohamed Mohany
Dr. Mohammad Waseem
Prof. Dr. Salim S. Al-Rejaie
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• diabetes
• diabetic nephropathy
• molecular mechanisms
• therapeutic approaches
• nanomedicine, drug targeting
• oxidative stress
• inflammation, apoptosis
• nephropathy biomarkers